Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of Alberta

$17,500.00

Cost-Effectiveness of Early versus Late Initiation of Biologic Therapy in the Management of Crohn's Disease

FY 2015-16

Summary
Crohn's disease is a chronic condition characterized by a relapsing and remitting course of intestinal inflammation. Currently, there is no curative treatment for Crohn's disease, and patients therefore require lifelong treatment in an attempt to induce and maintain clinical remission, improve quality of life, and prevent surgery. The introduction of biologic therapy to treat Crohn's disease has led to better patient outcomes, including increased quality of life, steroid discontinuation, and reduced hospitalization and surgery rates. Although effective, the cost of biologic therapy is significant, ranging from $21,000 to $25,000 annually per patient. In our current society, growing healthcare costs and increased constraints on healthcare budgets have prompted us to consider both the goals and outcomes associated with biologic therapy, as well as the costs of achieving these goals.It has been demonstrated that early initiation (2 years since diagnosis) of biologic therapy results in higher patient response rates, and therefore improved patient outcomes later in their disease course. It is hypothesized that early intervention of biologic therapy prevents the onset of structural, irreversible bowel damage, and therefore reduces long-term complications associated with Crohn's disease. Based on these findings, our study aims to determine when in the disease course it is most cost-effective to initiate biologic therapies for patients with Crohn's disease. This will provide important information to clinicians to help them make decisions regarding if and when biologics should be provided as an option for their patients.
Program
Master's Award: Canada Graduate Scholarships
Location
Alberta, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
349962
Name
Beilman Candace L
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Cost-Effectiveness of Early versus Late Initiation of Biologic Therapy in the Management of Crohn's Disease
Programtype2
Studentship Programs
Orgnameinp2
University of Alberta
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Adalimumab; Anti-Tnf; Biologic Therapy; Cost-Utility Analysis; Crohn'S Disease; Health Economics; Infliximab
Abstract
Crohn's disease is a chronic condition characterized by a relapsing and remitting course of intestinal inflammation. Currently, there is no curative treatment for Crohn's disease, and patients therefore require lifelong treatment in an attempt to induce and maintain clinical remission, improve quality of life, and prevent surgery. The introduction of biologic therapy to treat Crohn's disease has led to better patient outcomes, including increased quality of life, steroid discontinuation, and reduced hospitalization and surgery rates. Although effective, the cost of biologic therapy is significant, ranging from $21,000 to $25,000 annually per patient. In our current society, growing healthcare costs and increased constraints on healthcare budgets have prompted us to consider both the goals and outcomes associated with biologic therapy, as well as the costs of achieving these goals.It has been demonstrated that early initiation (2 years since diagnosis) of biologic therapy results in higher patient response rates, and therefore improved patient outcomes later in their disease course. It is hypothesized that early intervention of biologic therapy prevents the onset of structural, irreversible bowel damage, and therefore reduces long-term complications associated with Crohn's disease. Based on these findings, our study aims to determine when in the disease course it is most cost-effective to initiate biologic therapies for patients with Crohn's disease. This will provide important information to clinicians to help them make decisions regarding if and when biologics should be provided as an option for their patients.
Competitiondate
201512
Approvedterm2
1 yr 0 mth
Pinamesdelim
Beilman, Candace L
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~